Aeovian- John F. Kincaid CSO � Selective mTORC1 inhibitor

Aeovian is a San Francisco Bay Area-based research stage biopharmaceutical company aiming to discover, develop and commercialize  therapeutics for the treatment of rare and age-related diseases.  They are developing compounds to modulate molecular pathways that address the underlying causes of disease initiation and progression, such as oxidative, cellular and environmental stress. 

​Their highly selective therapeutics that inhibit the mTORC1 pathway. Genetic mutations and aging result in abnormal activation of mTORC1; normalization of its aberrant activity is, therefore, necessary to combat rare and age-related disease pathologies and enable therapeutic treatment. Addressing the mTORC1 pathway has been challenging to-date however, because chronic treatment with conventional, non-selective mTOR inhibitors, such as rapamycin and Everolimus, leads to off-target inhibition of mTORC2 which results in dose-limiting deleterious effects on metabolic health and immune function. The associated toxicity leads to severe clinical adverse events that significantly reduce treatment safety, decrease compliance, and compromise therapeutic efficacy.